Experts urge Europe to tax alcohol and junk food heavily enough to bankroll the health and social costs of their own consumption

In a report released on 29 April 2026, a consortium of public‑health researchers and economists argued that the persistently rising mortality from liver disease—estimated at roughly 284 000 European lives each year—has reached a point where the conventional reliance on voluntary moderation and public awareness campaigns is evidently insufficient, prompting a call for fiscal measures of a magnitude sufficient to generate revenues capable of offsetting the combined expenditures of health services, criminal‑justice interventions and social‑welfare provisions that are presently strained by the same consumables.

The authors of the study emphasized that any tax increase on alcoholic beverages and foods high in saturated fats, sugars or salts should be calibrated not merely to discourage excessive intake but expressly to raise funds that directly match—or ideally surpass—the projected fiscal burden imposed by liver‑related morbidity, thereby converting the market price of the offending products into a self‑financing mechanism for the public systems that are forced to treat, police and support the affected populations.

While the recommendation appears straightforward, it simultaneously reveals the systemic reluctance of European governments to confront the underlying conflict of interest inherent in allowing profitable industries to continue operating under a regime of modest excise duties, a reluctance that the report implicitly criticizes by highlighting the predictable pattern of incremental tax adjustments that never quite reach the level required to achieve fiscal neutrality, thus perpetuating a cycle in which the very entities that profit from harmful consumption are indirectly subsidised by the societies they endanger.

By framing the tax hike as a pragmatic solution rather than a moralistic prohibition, the experts hope to sidestep the political opposition that typically accompanies stricter regulation, yet the document itself underscores that without a decisive and sizable price signal, the projected reduction in liver disease mortality will remain an aspirational target rather than an attainable outcome, thereby exposing a glaring disconnect between policy rhetoric and the economic realities of public‑health financing across the continent.

Published: April 30, 2026